Century Therapeutics, Inc. (IPSC)

Century Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	6.59	2.24	5.2	-	-
Revenue Growth (YoY)	194.81%	-57.01%	-	-	-
Cost of Revenue	107.24	92.71	97.17	75.65	-
Gross Profit	-100.66	-90.48	-91.97	-75.65	-
Selling, General & Admin	34.51	34.71	31.86	19.24	9.5
Research & Development	-	-	-	-	39.68
Operating Expenses	34.51	34.71	31.86	19.24	49.18
Operating Income	-135.17	-125.18	-123.83	-94.88	-49.18
Interest Expense	-	-0.54	-1.43	-1.28	-0.38
Interest & Investment Income	13.01	12.68	4.42	0.38	0.7
Other Non Operating Income (Expenses)	0.35	-0.38	-	-	-
EBT Excluding Unusual Items	-121.81	-113.43	-120.84	-95.78	-48.85
Impairment of Goodwill	-4.33	-	-	-	-
Asset Writedown	-	-16.37	-	-	-
Other Unusual Items	1.36	-	-	-	-
Pretax Income	-124.78	-134.79	-130.84	-95.78	-53.58
Income Tax Expense	1.79	1.88	0.09	0.04	-
Net Income	-126.57	-136.67	-130.93	-95.82	-53.58
Net Income to Common	-126.57	-136.67	-130.93	-95.82	-53.58
Shares Outstanding (Basic)	79	59	58	32	7
Shares Outstanding (Diluted)	79	59	58	32	7
Shares Change (YoY)	32.60%	2.70%	78.30%	332.95%	10.43%
EPS (Basic)	-1.61	-2.30	-2.27	-2.96	-7.16
EPS (Diluted)	-1.61	-2.30	-2.27	-2.96	-7.16
Free Cash Flow	-110.29	-102.08	-16.55	-133.97	-51.09
Free Cash Flow Per Share	-1.40	-1.72	-0.29	-4.14	-6.83
Operating Margin	-2051.39%	-5600.94%	-2381.82%	-	-
Profit Margin	-1920.87%	-6115.12%	-2518.41%	-	-
Free Cash Flow Margin	-1673.84%	-4567.52%	-318.37%	-	-
EBITDA	-121.86	-112.14	-115.39	-91.14	-47.77
D&A For EBITDA	13.3	13.04	8.44	3.75	1.4
EBIT	-135.17	-125.18	-123.83	-94.88	-49.18

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q